Ideaya Biosciences Inc.

Company Overview

Business Model: IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on the discovery, development, and commercialization of transformative therapies for cancer. The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics with internal capabilities in identifying and validating translational biomarkers. Its pipeline emphasizes synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. The clinical development strategy involves evaluating product candidates in rational combinations and earlier in the course of disease (adjuvant and neoadjuvant settings) to maximize impact.

Market Position: IDEAYA Biosciences, Inc. is developing a pipeline of nine potential first-in-class product candidates across four clinical focus areas. The company holds Breakthrough Therapy designation for darovasertib in neoadjuvant primary uveal melanoma (UM) and Fast Track designations for darovasertib in combination with crizotinib for metastatic UM (mUM) and for IDE161 in specific ovarian and breast cancer indications. Darovasertib also has Orphan Drug designation in UM. The company notes it is not aware of other companies actively developing clinical-stage therapeutics directed to PKC as a target for solid tumors (darovasertib) or bispecific ADCs targeting both B7H3 and PTK7 (IDE034). However, the synthetic lethality field, beyond PARP inhibitors, has no approved small molecule inhibitors to date.

Recent Strategic Developments:

• August 2025: Entered into an exclusive license agreement with Servier for the development and commercialization of darovasertib in all countries worldwide except for the United States, receiving an upfront payment of $210.0 million.
• December 2025: Completed full enrollment of 437 patients in the potentially registration-enabling Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib for first-line (1L) mUM patients (HLA*A2(-)). Topline data, including progression-free survival (PFS), is expected in the first quarter of 2026, potentially enabling an accelerated approval filing in the United States.
• October 2025: Reported positive data from the single-arm Phase 2 OptimUM-01 trial of darovasertib in combination with crizotinib in 1L mUM patients, showing a confirmed objective response rate (ORR) of 34% (14/41) and median overall survival (OS) of 21.1 months across all patients.
• 2025: Initiated a randomized Phase 3 trial (OptimUM-10) of darovasertib monotherapy in the neoadjuvant setting of primary UM, targeting enrollment of approximately 450 patients by the first half of 2027.
• First Half 2026 (Planned): Plans to initiate a global Phase 3 combination trial (OptimUM-11) of darovasertib and crizotinib in the adjuvant setting of primary UM, enrolling approximately 450 patients.
• April 2025: Received U.S. Investigational New Drug (IND) clearance for IDE849, a DLL3 TOP1 ADC, with initial data from a global Phase 1 trial expected and a monotherapy registrational trial targeted for initiation by the end of 2026.
• Q4 2025: Received IND clearance for IDE034, a B7H3/PTK7 bispecific TOP1 ADC, with first-patient-in (FPI) in a Phase 1 dose-escalation trial expected in the first quarter of 2026.
• Q3 2025: Received IND clearance for IDE892, an MTA-cooperative PRMT5 inhibitor, with a Phase 1 dose escalation trial expected to begin in the first quarter of 2026.
• January 2026: Received IND clearance for IDE574, a KAT6/7 dual inhibitor, with a Phase 1 dose escalation trial expected to begin in the first quarter of 2026.
• December 2025: GlaxoSmithKline (GSK) notified IDEAYA Biosciences, Inc. of its intention to terminate the collaboration agreement for the Pol Theta (IDE705) and Werner Helicase (IDE275) programs, effective March 9, 2026. IDEAYA Biosciences, Inc. intends to continue the development of these programs.

Geographic Footprint: IDEAYA Biosciences, Inc. retains all commercial rights to darovasertib in the United States. Servier holds exclusive development and commercialization rights for darovasertib in all countries worldwide except for the United States. IDEAYA Biosciences, Inc. owns or controls worldwide commercial rights for IDE397, IDE892, IDE034, IDE161, IDE574, and IDE275, IDE705, and all commercial rights outside of Greater China for IDE849. Clinical trials are conducted globally, including in China (for IDE849 by Jiangsu Hengrui Pharmaceuticals Co., Ltd.) and planned global trials for darovasertib. The company's corporate headquarters and primary laboratory facilities are in South San Francisco, California, with additional corporate office space in San Diego, California.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 100.0% (as no cost of revenue is reported, total revenue is equivalent to gross profit)
• Operating Margin: -72.8%
• Net Margin: -52.0%

Investment in Growth:

• R&D Expenditure: $314.7 million (143.9% of revenue)
• Capital Expenditures: $2.4 million
• Strategic Investments:
  • Upfront payment received from Servier: $210.0 million (August 2025)
  • Milestone payment to Novartis for darovasertib Breakthrough Therapy designation: $1.0 million (April 2025)
  • Milestone payment to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for IDE849 Phase 1 FPI: $2.0 million (October 2025)
  • Milestone payment to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. for IDE034 Phase 1 FPI: $5.0 million (expected Q1 2026)

Pipeline Overview

Darovasertib for Uveal Melanoma

Financial Performance:

• Revenue: Not segment-specific, included in collaboration revenue.
• Operating Margin: Not segment-specific.
• Key Growth Drivers: Advancing darovasertib in combination with crizotinib in a potentially registration-enabling Phase 2/3 trial (OptimUM-02) for 1L mUM (HLA*A2(-)), with topline data expected in Q1 2026. Initiated a randomized Phase 3 trial (OptimUM-10) in neoadjuvant UM in 2025, and plans to initiate a global Phase 3 combination trial (OptimUM-11) in adjuvant UM in H1 2026. Positive Phase 2 data from OptimUM-01 and OptimUM-09 support broader development.

Product Portfolio:

• Darovasertib: An oral, potent, and selective small molecule inhibitor of protein kinase C (PKC).

Market Dynamics:

• Annual incidence of primary UM is estimated at >10,000 patients globally and >3,000 in the United States.
• Annual incidence of newly diagnosed mUM patients is estimated between 4,000-5,000 globally and approximately 1,500 in the United States.
• Approximately 95% of UM patients harbor activating GNAQ/11 mutations.
• The majority of mUM patients are of the HLA*A2(-) serotype (60-65%).
• Currently, there are no FDA-approved systemic therapies for primary UM and no FDA-approved therapies for patients with HLA*A2(-) mUM.

Operational Metrics:

• OptimUM-02 (Phase 2/3, 1L mUM, HLA*A2(-)): Completed full enrollment of 437 patients in December 2025.
• OptimUM-01 (Phase 2, 1L mUM): Reported positive data in October 2025 from 44 patients (41 efficacy-evaluable), showing a confirmed ORR of 34% (14/41), median duration of response (mDOR) of 9.0 months, disease control rate (DCR) of 90%, median PFS of 7.0 months, and median OS of 21.1 months. Enrollment of ~100 HLA*A2(+) patients expected to complete by Q2 2026.
• OptimUM-10 (Phase 3, Neoadjuvant UM): Initiated in 2025, enrolling ~450 patients (plaque brachytherapy-eligible (PB) and enucleation-eligible (EN)). Enrollment expected to complete by H1 2027.
• OptimUM-09 (Phase 2, Neoadjuvant UM): Reported positive data in October 2025 from 95 patients. Ocular tumor shrinkage observed in ~83% (78/94) of patients. Among evaluable EN patients, eye preservation rate was 57% (24/42), increasing to 95% (19/20) in patients with ≥20% tumor shrinkage. Among PB-eligible patients, ~70% (26/37) achieved a reduction in predicted radiation dose to the eye.

ADC / DNA Damage Response (DDR) Combinations

Key Growth Drivers: Focus on exploring combinations of topoisomerase I inhibitor–based ADCs (TOP1 ADCs) and selective inhibitors of the DDR pathway, particularly poly (ADP-ribose) glycohydrolase (PARG). Preclinical data show robust and durable tumor shrinkage with IDE161 in combination with IDE849 and IDE034.

Product Portfolio:

• IDE849 / SHR-4849: A potential first-in-class, DLL3 TOP1 ADC.
• IDE034: A potential first-in-class, B7H3/PTK7 bispecific TOP1 ADC.
• IDE161: A potential first-in-class, oral small molecule PARG inhibitor.
• IDE705: A potential first-in-class, oral small molecule inhibitor of the helicase domain of Pol Theta.

Market Dynamics:

• DLL3 is expressed at high frequency in ~85% of small-cell lung cancer (SCLC) and 64% of neuroendocrine carcinomas (NEC), with limited extracellular expression in normal tissues.
• B7H3/PTK7 has been found to be co-expressed in ~30-40% of lung, colorectal, breast, and ovarian cancers.
• Pol Theta inhibition is a synthetic lethal vulnerability in tumor cells harboring double strand break repair defects, such as those with BRCA1 or BRCA2 mutations.

Operational Metrics:

• IDE849: Jiangsu Hengrui Pharmaceuticals Co., Ltd. presented positive initial Phase 1 data in September 2025 from 100 patients (87 refractory SCLC) in China. Efficacy (n=71 SCLC) showed a confirmed ORR of 14.1% and DCR of 90%. Median PFS was 6.7 months (doses ≥2.4 mg/kg). Safety profile was manageable, with Grade 3+ treatment-related adverse events (TRAEs) in 48% of patients. U.S. IND clearance received in April 2025 for a global Phase 1 trial. A Phase 1 clinical combination trial with IDE161 is targeted for Q2 2026.
• IDE034: IND clearance received in Q4 2025. FPI in Phase 1 dose-escalation trial expected in Q1 2026.
• IDE161: Currently in a Phase 1 dose optimization trial. Fast Track designations received in September 2023 for adult, pretreated, platinum-resistant advanced or metastatic ovarian cancer patients with BRCA1/2 mutations and for adult, pretreated, advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 (Her2-) and BRCA1/2 mutant breast cancer patients.
• IDE705: GlaxoSmithKline (GSK) terminated its collaboration agreement in December 2025 (effective March 9, 2026). IDEAYA Biosciences, Inc. plans to begin preclinical studies evaluating IDE705 to enhance the efficacy of TOP1 ADCs.

MTAP Pathway

Key Growth Drivers: Focus on solid tumors with methylthioadenosine phosphorylase (MTAP) gene deletions, which create a synthetic lethal vulnerability when MAT2A is pharmacologically inhibited. Evaluating rational combinations to inhibit key nodes in the MTAP pathway.

Product Portfolio:

• IDE397: A potential first-in-class, oral small molecule inhibitor of methionine adenosyltransferase 2a (MAT2A).
• IDE892: A potential first-in-class, oral small molecule MTA-cooperative PRMT5 inhibitor.

Market Dynamics:

• No currently approved therapies for patients with MTAP-deleted solid tumors.
• MTAP-deletion occurs in approximately 15% of all solid tumors, including >15% of non-small cell lung cancer (NSCLC) and >25% of urothelial cancer (UC).
• The U.S. annual incidence of MTAP-deleted tumors is estimated at approximately 62,000 patients across priority tumor types (UC, NSCLC, pancreatic cancer).

Operational Metrics:

• IDE397: Initial Phase 1/2 data presented in September 2025 from 19 patients (16 evaluable) with late-line MTAP-deleted UC in combination with Trodelvy. Confirmed ORR of 31% (5/16) and DCR of 81% (13/16). Median PFS and DOR had not been reached. The safety profile was manageable. Additional data from this combination trial in MTAP-deleted UC is targeted for a medical conference in 2026.
• IDE892: IND clearance received in Q3 2025. A Phase 1 dose escalation trial is expected to begin in Q1 2026, with the goal of advancing into combination trials with IDE397 in MTAP-deleted NSCLC in Q2 2026.

Next Generation Therapies

Key Growth Drivers: Development of therapies designed to intercept fundamental dependencies underpinning tumor driver pathways, potentially overcoming genetic and epigenetic tumor heterogeneity.

Product Portfolio:

• IDE574: A potential first-in-class, oral small molecule equipotent dual inhibitor of lysine acetyltransferase (KAT) 6 and 7.
• IDE275: A potential first-in-class, oral small molecule inhibitor of the helicase domain of the Werner protein (WRN).

Market Dynamics:

• KAT6 and KAT7 are epigenetic modulators of cell identity and lineage commitment programs corrupted by oncogenic transformation. Dual KAT6/7 inhibition shows robust anti-tumor activity in preclinical models with 8p11 amplifications.
• WRN helicase inhibition is a synthetic lethal vulnerability in MSI-High tumor models. Microsatellite instability (MSI)-High tumors represent ~3-4% of all cancers, including ~28% of endometrial, 10% of ovarian, and 15% of gastrointestinal tumors.

Operational Metrics:

• IDE574: IND clearance received in January 2026. A Phase 1 dose escalation trial in patients with breast, lung, prostate, and colorectal cancers is targeted for Q1 2026.
• IDE275: GlaxoSmithKline (GSK) terminated its collaboration agreement in December 2025 (effective March 9, 2026). IDEAYA Biosciences, Inc. intends to complete the dose expansion portion of the Phase 1 trial.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: IDEAYA Biosciences, Inc. has never declared or paid any cash dividends on its common stock and does not anticipate paying cash dividends in the foreseeable future.
• Dividend Yield: 0%
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $112.8 million (as of December 31, 2025)
• Total Debt: Not disclosed.
• Net Cash Position: $1,049.7 million (Cash, cash equivalents, and marketable securities as of December 31, 2025)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no debt is disclosed.

Cash Flow Generation:

• Operating Cash Flow: $(71.1) million (for the year ended December 31, 2025)
• Free Cash Flow: $(73.5) million (Operating Cash Flow of $(71.1) million minus Capital Expenditures of $2.4 million for the year ended December 31, 2025)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: IDEAYA Biosciences, Inc. relies entirely on third parties for the manufacture of its product candidates and biomarker diagnostics for preclinical and clinical testing, and for future commercial manufacturing. The company does not own or operate any manufacturing facilities and has no plans to establish them. Manufacturing agreements are established with Contract Manufacturing Organizations (CMOs) for active pharmaceutical ingredient (API) synthesis, drug product manufacturing, packaging, labeling, and distribution. The biochemical or synthetic processes for small molecules and antibody-drug conjugates are believed to be amenable to scale-up using standard manufacturing equipment and processes.

Supply Chain Architecture: Key Suppliers & Partners:

• API Synthesis: STA Pharmaceutical Hong Kong Limited Pharmaceutical (for darovasertib, IDE397), Pharmaron (for IDE161, IDE892, IDE574).
• Formulation & Manufacturing: STA Pharmaceutical, Patheon Inc. (for darovasertib), STA Pharmaceutical (for IDE397, IDE161, IDE892, IDE574). Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. provide development manufacturing services for in-licensed ADCs (IDE034 and IDE849, respectively).
• Clinical Services: Contract Research Organizations (CROs).
• Technology/Diagnostic Partners: Foundation Medicine, Guardant Health, Tempus (for biomarker identification and patient selection).

Facility Network:

• Manufacturing: Relies on third-party CMOs.
• Research & Development:
  • South San Francisco, California: Leases approximately 44,000 square feet of laboratory and office facilities (commenced August 2024), expanded by approximately 11,321 rentable square feet in January 2025.
  • San Diego, California: Leases approximately 5,700 square feet of corporate office space (commenced December 2023, expires March 2028).
• Distribution: Relies on third-party CMOs.

Operational Metrics: Not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: IDEAYA Biosciences, Inc. plans to build its own sales force to commercialize approved products in the United States and potentially in Europe and other selected foreign countries for pipeline products beyond darovasertib.
• Channel Partners: An exclusive license agreement with Servier covers the development and commercialization of darovasertib outside the United States. The company may also enter into distribution and other marketing or commercialization arrangements with additional third parties.
• Digital Platforms: Not explicitly disclosed.

Customer Portfolio: Enterprise Customers: Not explicitly named. Strategic Partnerships:

• Servier: Exclusive license for darovasertib outside the United States.
• Pfizer Inc.: Clinical Trial Collaboration and Supply Agreements for darovasertib in combination with crizotinib.
• Gilead Sciences, Inc.: Clinical Study Collaboration and Supply Agreements for IDE397 in combination with Trodelvy.
• Cancer Research UK and University of Manchester: Exclusive in-license for PARG inhibitors, including IDE161.
• Biocytogen Pharmaceuticals (Beijing) Co. Ltd.: Option and License Agreement for IDE034.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.: License Agreement for IDE849. Customer Concentration: Not explicitly disclosed.

Geographic Revenue Distribution:

• United States: IDEAYA Biosciences, Inc. retains all commercial rights for darovasertib and worldwide commercial rights for IDE397, IDE892, IDE034, IDE161, IDE574, IDE275, IDE705.
• Outside United States: Servier holds exclusive rights for darovasertib.
• Outside Greater China: IDEAYA Biosciences, Inc. holds commercial rights for IDE849.
• Growth Markets: Not explicitly detailed beyond general international expansion plans.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are highly competitive, characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. A significant number of product candidates are under development. The most common cancer treatments include surgery, radiation, and drug therapy (chemotherapy, hormone therapy, targeted drug therapy, or combinations). Synthetic lethality is an emerging class of precision medicine targets, with limited approvals to date (primarily PARP inhibitors).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Darovasertib (PKC inhibitor for UM):
  • PKC Inhibitors (preclinical): Varsity Pharma (CLL), Aquilon (PKC theta), Windtree Therapeutics (atypical PKC iota).
  • UM Therapies: Replimune (RP-2, oncolytic immunotherapy, registration-enabling), iOnctura (Roginolisib, PI3K delta inhibitor, Phase 2), Novartis (DYP688, ADC, Phase 1/2), Immatics (anzu-cel/IMA203, PRAME-targeting T cell therapy), Aura Biosciences (bel-sar, VDC, local treatment).
  • Commercialized UM Therapy: Immunocore (Tebentafusp/Kimmtrak, HLA*A2(+) mUM).
• IDE849 (DLL3 TOP1 ADC):
  • DLL3-targeting BiTEs: Amgen (Tarlatamab/Imdelltra, accelerated approval May 2024), Zelgen, Boehringer Ingelheim, Daiichi Sankyo (Phase 3/2).
  • DLL3 ADCs (Topoisomerase I inhibitor payloads): Zai Lab (ZL-1310, Phase 3), Roche, Zhang Jiang, Baili (Phase 1).
  • DLL3-targeting Radiopharmaceuticals: Abdera, Molecular Partners, Novartis (Phase 1).
• IDE034 (B7H3/PTK7 bispecific TOP1 ADC): No other bispecific ADCs targeting both B7H3 and PTK7 are known.
  • Mono-antigen B7H3 ADCs: Merck, Hansoh/GSK, Medilink, Minghui (Phase 3); BeOne, Duality, Innovent, Mabwell, MacroGenics (earlier phases).
  • Mono-antigen PTK7 ADCs: Day One, Kelun, Kivu, Lilly (Phase 1).
• IDE161 (PARG inhibitor): 858 Therapeutics (ETX-19477, Phase 1). Other PARG inhibitors (Phase 1): Danatlas, Evopoint, FoRx, SynRx. Preclinical: Aigen, Alivexis, Azkarra, Nodus Oncology, Satya Pharma Innovations, QuantX.
• IDE705 (Pol Theta inhibitor): Artios Pharma (ART-6043, Phase 1/2). Other Pol Theta inhibitors (Phase 1): Danatlas, Gilead Sciences, Inc., Moma Therapeutics, Simcere, SynRx. IND-enabling: Breakpoint Therapeutics, QuantX.
• IDE397 (MAT2A inhibitor): Servier (S095035, Phase 1/2). Insilico Medicine, BeOne Medicines (ISM3412, BG-89894, Phase 1). Preclinical: Genhouse Bio, Hanmi, ScinnoHub, SK Biopharma, Shouyao.
• IDE892 (MTA-cooperative PRMT5 inhibitor): Bristol Myers Squibb (navlimetostat/BMS-986504, Phase 2/3). Amgen (AMG-193), AstraZeneca (AZD-3470), BeOne (BGB-58067), Tango (vopimetostat/TNG462) (Phase 1/2). At least ten other companies (Phase 1), more than ten (preclinical).
• IDE574 (KAT6/7 dual inhibitor): Pfizer Inc. (KAT6/7 dual inhibitor, Phase 1; KAT6A inhibitor prifetrastat/PF-07248144, Phase 3). Other KAT6 inhibitors (Phase 1): Jiangsu Hengrui Pharmaceuticals Co., Ltd., Menarini, Olema. Preclinical: Isosterix, Prelude, Qubit.
• IDE275 (WRN inhibitor): Vividion (VVD-133214, Phase 1). Novartis (HRO-761), Nimbus Therapeutics (NDI-219216) (non-covalent WRN inhibitors, Phase 1). Eikon, MOMA Therapeutics (Phase 1). Preclinical: Genhouse, Insilico, Puhe.
• Preclinical Synthetic Lethality: AstraZeneca (Lynparza), Pfizer Inc. (Talzenna), GlaxoSmithKline (GSK) (Zejula), Roche. Early-stage: 858 Therapeutics, Artios, Breakpoint Therapeutics, Eikon, FoRx Therapeutics, Repare Therapeutics, Ryvu Therapeutics, Tango, Vividion, Xpose.

Competitive Response Strategy: IDEAYA Biosciences, Inc. aims to prioritize and advance first-in-class, differentiated precision oncology therapies and rational combinations. The company leverages its core development capabilities to broaden its precision therapy pipeline, including target identification and validation for new targets and biomarkers (e.g., CDKN2A program). It selectively establishes relationships with third parties to accelerate pipeline development, strengthen capital resources, and maximize commercial potential, and collaborates with leaders in diagnostics to identify defined patient populations.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Operating results may fluctuate significantly due to factors outside the company's control. The industry is highly competitive with rapid technological and scientific change. The incidence and prevalence of target patient populations are estimations, and if smaller than estimated, could harm the business. Negative perceptions of synthetic lethality therapeutics could adversely affect development and regulatory approvals.
• Technology Disruption: The precision medicine target and biomarker discovery platform is novel and may not be effective at identifying targets or biomarkers. The successful development of targeted therapeutics is highly uncertain, with potential for preclinical and clinical failures.
• Customer Concentration: Not explicitly disclosed as a material risk.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Heavy reliance on third parties for manufacturing product candidates and key raw materials for preclinical, clinical, and future commercial needs. Loss of a sole-source supplier or inability to obtain adequate supplies at acceptable costs could delay or impair development and commercialization efforts.
• Geographic Concentration: Corporate headquarters in the San Francisco Bay Area exposes the company to risks from natural disasters like earthquakes and wildfires. Reliance on foreign Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) introduces risks related to geopolitical conflicts, trade restrictions, and sanctions (e.g., potential impact of the BIOSECURE Act on PRC-based suppliers).
• Capacity Constraints: A limited number of manufacturers operate under cGMP regulations, potentially leading to competition for manufacturing facilities, especially during global disruptions.

Financial & Regulatory Risks

• Market & Financial Risks: IDEAYA Biosciences, Inc. is a clinical-stage company with no commercial products, has incurred significant losses since inception ($736.5 million accumulated deficit as of December 31, 2025), and anticipates continued losses. Substantial additional financing will be required, and failure to obtain it on acceptable terms could force delays or termination of development programs. Raising capital may dilute stockholders or involve restrictive debt covenants. The stock price may be volatile. The ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• Foreign Exchange: While not having a significant impact in recent years, exchange rate fluctuations remain a potential risk.
• Credit & Liquidity: The majority of cash and equivalents are held in accounts with major financial institutions, exceeding insured limits, posing a risk in case of institutional failure. Inadequate funds could lead to delays or termination of development programs.
• Regulatory & Compliance Risks: Inability to obtain or delays in regulatory approval for product candidates (including companion diagnostics) could prevent commercialization. Even with Fast Track or Breakthrough Therapy designations, faster development or approval is not guaranteed. Accelerated approval pathways require confirmatory trials, and failure to verify clinical benefit could lead to withdrawal of approval. Ongoing regulatory obligations post-approval are costly, and non-compliance or unforeseen problems could lead to restrictions, recalls, or withdrawal from the market. Business practices are subject to healthcare regulatory laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act), and non-compliance could result in significant penalties.
• Data Privacy: Actual or perceived failures to comply with evolving data protection, privacy, and security laws (e.g., GDPR, CCPA) and AI/ML regulations could adversely affect the business, leading to monetary damages, regulatory enforcement, and reputational harm.

Geopolitical & External Risks

• Geopolitical Exposure: Operating in a period of economic uncertainty and capital markets disruption, significantly impacted by geopolitical conflicts (e.g., Russia-Ukraine war) and potential changes in global trade policies. These could disrupt supply chains, manufacturing, clinical trials, and access to capital.
• Trade Relations: Changes to U.S. and other countries' trade policies, export control laws, sanctions, legislation, treaties, and tariffs could adversely affect financial performance and ability to obtain raw materials.
• Sanctions & Export Controls: The BIOSECURE Act (National Defense Authorization Act of 2026, § 851) restricts U.S. government agencies from using biotechnology equipment or services from "biotechnology companies of concern" (BCCs), which could impact reliance on foreign CROs and CMOs.

Innovation & Technology Leadership

Research & Development Focus: IDEAYA Biosciences, Inc. has built a fully integrated platform for precision medicine oncology, aiming to deliver a renewable pipeline of first-in-class programs. The Precision Medicine Research Platform encompasses capabilities for target and biomarker identification and validation, small molecule drug discovery, and translational biology.

Core Technology Areas:

• Proprietary Chemical Library: INQUIRE™, containing over 200,000 chemical compounds.
• Structure-based Drug Design: Enabled by extensive structural biology and crystallography capabilities.
• Machine-learning Engine: HARMONY™, a proprietary content-based engine for effective molecular design and structure-activity-relationship (SAR) cycles.
• Dual CRISPR Synthetic Lethality Library: DECIPHER™, developed in collaboration with the University of California, San Diego, focusing on DNA Damage Response (DDR) targets across various tumor suppressor genes and oncogenes, enabling evaluation of approximately 50,000 independent gene knockout combinations.
• Paralogous Gene Evaluation Platform: PAGEO™, an ongoing strategic collaboration with the Broad Institute, utilizing large-scale CRISPR paralog screening to discover synthetic lethality targets and biomarkers in ovarian cancer subtypes.
• Cancer Dependency Map Consortium: Membership in the Broad DepMap consortium enhances bioinformatics and cell-based screening efforts for synthetic lethality target and biomarker discovery and validation.

Innovation Pipeline: The company has active programs for several high-value targets. It plans to nominate a development candidate by the first half of 2026 for a novel program targeting CDKN2A, the most common co-alteration of MTAP, with strong combination potential with existing clinical-stage assets.

Intellectual Property Portfolio:

• Patent Strategy: The patent portfolio is built program-by-program to establish broad protection, including claims directed to composition of matter, pharmaceutical compositions, and methods of treatment. Protection is sought in the United States and key foreign jurisdictions.
• Patent Holdings (as of January 30, 2026):
  • Approximately 71 distinct patent families.
  • ~21 issued U.S. patents, ~37 pending U.S. applications, 15 pending Patent Cooperation Treaty (PCT) applications.
  • 65 issued foreign patents, ~185 pending foreign applications in ~40 foreign jurisdictions.
  • Expiration dates range from 2035 to 2046.
  • PKC program (darovasertib): ~7 issued U.S. patents, ~34 issued foreign patents, ~8 pending U.S. applications, ~2 pending PCT applications, and ~48 pending foreign applications. Expiration dates between 2035 and 2045. Jointly owned U.S. patent applications with Pfizer Inc. for certain combination treatments.
  • MAT2A program (IDE397): ~5 issued U.S. patents, ~9 issued foreign patents, ~11 pending U.S. applications, ~3 pending PCT applications, and ~69 pending foreign applications. Expiration dates between 2039 and 2045. Jointly owned U.S. and foreign applications with GlaxoSmithKline (GSK), Amgen, and Gilead Sciences, Inc. for combination treatments.
  • PARG program (IDE161): ~4 issued U.S. patents, ~17 issued foreign patents, ~8 pending U.S. applications, and ~67 pending foreign applications. Expiration dates between 2035 and 2044.
  • Preclinical pipeline: U.S. patent applications for Pol Theta (HR), WRN (MSI-High), PRMT5, KAT6A/7, ADC (DLL3), ADC (B7H3/PTK7), and certain next-generation Synthetic Lethality Therapeutics (SLT) programs.
• Licensing Programs:
  • Exclusive license agreement with Servier for darovasertib outside the United States.
  • Exclusive in-license agreements with Jiangsu Hengrui Pharmaceuticals Co., Ltd. for IDE849 and Biocytogen Pharmaceuticals (Beijing) Co. Ltd. for IDE034.
  • Exclusive in-license agreement with Cancer Research UK and University of Manchester for PARG inhibitors, including IDE161.
  • Exclusive license agreement with Novartis for darovasertib.
• IP Litigation: Not currently a party to any material litigation or legal proceedings.

Technology Partnerships:

• Strategic Alliances: Pfizer Inc. (clinical development of darovasertib), Gilead Sciences, Inc. (clinical evaluation of IDE397), Biocytogen Pharmaceuticals (Beijing) Co. Ltd. (IDE034), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (IDE849).
• Research Collaborations: University of California, San Diego (DECIPHER Dual CRISPR library), Broad Institute (PAGEO, DepMap consortium).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success is dependent on its ability to attract, retain, and motivate highly qualified management, clinical, scientific, and commercial personnel. The company is highly dependent on its senior management, including the President and Chief Executive Officer, and senior scientists.

Board Composition: As of December 31, 2025, females constitute 29% of the board of directors. The board of directors delegates oversight of cybersecurity risks to the Audit Committee, which is composed of members with diverse expertise including risk management, public accounting, biotechnology, and chief executive officer roles. The Audit Committee receives quarterly reports from management on cybersecurity risks and reports to the full board.

Human Capital Strategy

Workforce Composition:

• Total Employees: 145 (as of December 31, 2025)
• Geographic Distribution: Not explicitly disclosed beyond facility locations in South San Francisco, California, and San Diego, California.
• Skill Mix: 110 employees hold biology, chemistry, or other relevant scientific degrees, including 55 Ph.D.s.

Talent Management: Acquisition & Retention: The company views its employees as valuable assets and emphasizes hiring and retaining highly skilled professionals. It offers a challenging work environment, ongoing skills development, attractive career advancement, and a culture that rewards entrepreneurial initiative and exceptional execution.

• Hiring Strategy: Draws from large talent pools to find qualified individuals.
• Retention Metrics: Not disclosed.
• Employee Value Proposition: Focuses on challenging work, skills development, career advancement, and a culture of commitment, innovation, integrity, teamwork, objective decision-making, and empowered accountability.

Diversity & Development:

• Diversity Metrics: As of December 31, 2025, females comprise 48% of the workforce, 23% of the executive team, and 29% of the board of directors.
• Development Programs: Provides ongoing skills development and leadership development initiatives.
• Culture & Engagement: Emphasizes values of passionate commitment, fearless innovation, courageous integrity, respectful teamwork, objective decision-making, and empowered accountability.

Environmental & Social Impact

Environmental Commitments: Not explicitly disclosed in the provided filing. Supply Chain Sustainability: Not explicitly disclosed in the provided filing. Social Impact Initiatives: Not explicitly disclosed in the provided filing.

Business Cyclicality & Seasonality

Demand Patterns: The company's operating results may fluctuate significantly due to various factors, many of which are outside its control and difficult to predict. No specific seasonal trends are disclosed. Economic Sensitivity: The business is exposed to macroeconomic developments, including health epidemics or pandemics, macroeconomic uncertainties, social unrest, geopolitical hostilities, natural disasters, or other catastrophic events, which can impact business, operations, clinical trials, manufacturing, suppliers, and collaborators. The company is currently operating in a period of economic uncertainty and capital markets disruption. Industry Cycles: The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies and intense competition, which can influence product development and commercialization cycles.

Planning & Forecasting: Not explicitly disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: IDEAYA Biosciences, Inc.'s research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, and import/export of products are extensively regulated by government authorities in the United States and other countries.

• U.S. Drug Development Process: Involves preclinical testing (GLP), IND submission, IRB approval, human clinical trials (GCP, Phase 1/2/3), NDA submission, FDA advisory committee review, cGMP compliance inspections, and FDA review/approval. Expedited programs (Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval) are available for qualifying product candidates.
• U.S. Post-approval Requirements: Approved products are subject to ongoing regulatory requirements including manufacturing, labeling, packaging, storage, advertising, promotion, safety reporting, and post-marketing studies (Phase 4). The FDA may require Risk Evaluation and Mitigation Strategies (REMS).
• U.S. Orphan Drug Designation: Darovasertib has Orphan Drug designation for UM, potentially providing 7 years of market exclusivity upon approval, subject to certain conditions.
• FDA Regulation of Companion Diagnostics: Companion diagnostics are regulated as medical devices (Class I, II, or III) and require premarket clearance (510(k)) or approval (PMA) or de novo classification. Co-development with therapeutic products requires coordination between FDA centers.
• Regulation Outside the United States: Foreign regulatory approval processes vary, requiring separate Marketing Authorizations (MA). The EU uses centralized and national MA procedures, with the Clinical Trials Regulation (CTR) applicable since January 31, 2025, harmonizing clinical trial assessment.
• Data and Marketing Exclusivity (EU): New products may receive 8 years of data exclusivity and 2 years of market exclusivity, extendable to 11 years under certain conditions. Orphan medicinal products are entitled to 10 years of market exclusivity, extendable by 2 years with a Pediatric Investigation Plan (PIP).

Trade & Export Controls:

• Export Restrictions: The company is subject to U.S. and foreign trade policies, export control laws, sanctions, and tariffs.
• Sanctions Compliance: The National Defense Authorization Act of 2026 (NDAA), including the BIOSECURE Act (§ 851), restricts U.S. government agencies from procuring biotechnology equipment or services from "biotechnology companies of concern" (BCCs) controlled by foreign adversaries, which could impact the company's foreign CRO and CMO relationships.

Legal Proceedings: IDEAYA Biosciences, Inc. is not currently a party to any litigation or legal proceedings that management believes are likely to have a material adverse effect on its business.

Tax Strategy & Considerations

Tax Profile: IDEAYA Biosciences, Inc. has incurred net losses and has not recorded a federal or state income tax provision. The company maintains a full valuation allowance against its net deferred tax assets due to the uncertainty of realization.

• Net Operating Loss (NOL) Carryforwards (as of December 31, 2025):
  • Federal: $145.8 million ($11.6 million expiring starting 2037; $134.2 million arising after December 31, 2017, do not expire).
  • State: $93.9 million (expiring starting 2036).
• Research and Development Credit Carryforwards (as of December 31, 2025):
  • Federal: $17.1 million (expiring starting 2037).
  • State: $13.6 million (can be carried forward indefinitely).
• Orphan Drug Credits (ODC) (as of December 31, 2025): $27.3 million.
• Unrecognized Tax Benefits (as of December 31, 2025): $8.8 million.

Geographic Tax Planning: The company files income tax returns in the U.S. federal jurisdiction and in the states of Arizona, California, New Jersey, North Carolina, Pennsylvania, Texas, Utah, and Wisconsin.

Tax Reform Impact: The One Big Beautiful Bill Act, enacted in July 2025, modified certain business tax provisions, including the restoration of 100% bonus depreciation and the ability to expense domestic research and development costs. This act did not result in a material impact to the company’s income tax provision or effective tax rate.

Insurance & Risk Transfer

Risk Management Framework: IDEAYA Biosciences, Inc. maintains various insurance coverages to mitigate risks.

• Insurance Coverage:
  • Workers’ compensation insurance: Covers costs and expenses for employee injuries from hazardous materials.
  • Pollution insurance: Covers certain biological or hazardous waste exposure and contamination situations.
  • Cyber liability insurance: Maintained to cover potential financial, legal, business, or reputational losses from system interruptions or breaches.
  • Product liability insurance: Obtained and intended to be maintained to cover clinical trials, with plans to expand coverage for commercialized products.
• Risk Transfer Mechanisms: The company enters into standard indemnification arrangements with vendors, clinical trial sites, and other parties in the ordinary course of business. These arrangements generally provide for perpetual indemnification.